23.5 C
New York
Monday, June 8, 2026

Tag: regulatory approval

TowneBank and Old Point Financial Corporation Announce Expected Closing Date and Election Deadline for Merger

SUFFOLK, Va. and HAMPTON, Va., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Hampton Roads based TowneBank (NASDAQ: TOWN) and Old Point Financial Corporation (NASDAQCM: OPOF) (“Old Point”), the parent company of The Old Point National Bank of Phoebus (“Old Point National Bank”), today announced that they had received regulatory approval from the Federal Deposit Insurance Corporation (the “FDIC”) and the Bureau of Financial Institutions of the Virginia State Corporation Commission to complete the proposed merger of Old Point and Old Point National Bank with TowneBank. All regulatory approvals required for the transaction have now been received. The merger is expected to close on or about September 1, 2025, subject to the satisfaction of customary closing conditions.

Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven by Innovation and Unmet Need | DelveInsight

The outlook for the neuroblastoma treatment market is optimistic, fueled by progress in targeted therapies and immunotherapies. GD2-targeted immunotherapy is increasingly being incorporated into...

Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven by Innovation and Unmet Need | DelveInsight

The outlook for the neuroblastoma treatment market is optimistic, fueled by progress in targeted therapies and immunotherapies. GD2-targeted immunotherapy is increasingly being incorporated into...

TowneBank and Old Point Financial Corporation Announce Expected Closing Date and Election Deadline for Merger

SUFFOLK, Va. and HAMPTON, Va., Aug. 14, 2025 /PRNewswire/ -- Hampton Roads based TowneBank (NASDAQ: TOWN) and Old Point Financial Corporation (NASDAQCM: OPOF) ("Old Point"),...

Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights

- Dosed first patient in SURF302 for intermediate risk non-muscle invasive bladder cancer (IR NMIBC) - - Cash, cash equivalents, and marketable securities of $296.3...

Biotech Stocks Rally as Oncology Market Targets $866B by 2034

Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Aug. 14, 2025 /PRNewswire/ -- Equity Insider News Commentary – Despite alarming federal budget cuts...

Breakthrough T1D-Authored Paper Paves the Way for Beta Cell Replacement Therapies on the Path to Cures for Type 1 Diabetes

Changes recommended in clinical trial design to include the voice of more people living with type 1 diabetes in evaluating therapy benefits NEW YORK, Aug....

Rogers enters into definitive agreement to sell portfolio of data centres

Rogers will continue to sell connectivity and data centre services into the facilities

HLS Therapeutics Announces Q2 2025 Financial Results

Adjusted EBITDA grew 21% in Q2 and 29% year-to-date Cash from operations grew 83% in Q2 and 147% year-to-dateMade principal repayments on the Company's...

FRONTERA ANNOUNCES SECOND QUARTER 2025 RESULTS

Recorded $455.2 million in Net Loss Mainly due to Non-Cash Impairment Charges Related to its Interest in the Corentyne License and Ecuadorian Assets Increased Total...

FRONTERA ANNOUNCES SECOND QUARTER 2025 RESULTS

Recorded $455.2 million in Net Loss Mainly due to Non-Cash Impairment Charges Related to its Interest in the Corentyne License and Ecuadorian Assets Increased Total...

Shilpa Medicare’s NorUDCA Makes History as First Approved NAFLD Therapy Worldwide

Shilpa Medicare emerges as the global pioneer to receive approval for NorUDCA, offering new hope to over a billion people affected by Non-Alcoholic Fatty...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsRegulatory approval